CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details

Project Number PC0151-000
Brand Name Xalkori
Generic Name Crizotinib
Strength 200 mg & 250 mg
Tumour Type Lung
Indication ROS1-positive advanced Non-Small Cell Lung Cancer
Funding Request As a single agent as first-line treatment for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC)
Review Status Complete
Pre Noc Submission No
NOC Date August 28, 2017
Manufacturer Pfizer Canada Inc.
Sponsor Cancer Care Ontario Lung Cancer Drug Advisory Committee
Submission Date October 30, 2018
Submission Deemed Complete November 13, 2018
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline ‡ November 13, 2018
Check-point meeting January 22, 2019
pERC Meeting April 18, 2019
Initial Recommendation Issued May 3, 2019
Feedback Deadline ‡ May 17, 2019
Final Recommendation Issued May 23, 2019
Notification to Implement Issued June 7, 2019
Therapeutic Area ROS1-positive advanced non-small cell lung cancer (NSCLC)
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.